1-[2-[Bis[4-(Trifluoromethyl)Phenyl]Methoxy]Ethyl]-5,6-Dihyd

CAS : 110283-66-4

Ref. 3D-FB102809

Informations sur le produit

• Nom: 1-[2-[Bis[4-(Trifluoromethyl)Phenyl]Methoxy]Ethyl]-5,6-Dihyd
• Synonymes: 1-(2-(Bis(4-(trifluoromethyl)phenyl)methoxy)ethyl)-1,2,5,6-tetrahydropyridine-3-carboxylicacidhydrochloride, 1-(2-{Bis[4-(Trifluoromethyl)Phenyl]Methoxy}Ethyl)-1,2,5,6-Tetrahydropyridine-3-Carboxylic Acid Hydrochloride (1:1), 1-[2-[Bis(4-(Trifluoromethyl)Phenyl)Methoxy]Ethyl]-1,2,5,6-Tetrahydropyridine-3-Carboxylic Acid, 1-[2-bis[4-(Trifluormethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydropyridine3-carboxylic acid hydrochloride, 3-Pyridinecarboxylic acid, 1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydro-, hydrochloride, 3-Pyridinecarboxylic acid, 1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydro-, hydrochloride (1:1), 3-Pyridinecarboxylicacid,1,2,5,6-Tetrahydro-1-(2-(Bis(4-(Trifluoromethyl)Phen, CI966HCl, Ci 966, Ci 966 Hydrochloride, Ci966

Description

1-[2-[Bis[4-(Trifluoromethyl)phenyl]methoxy]ethyl]-5,6-dihydro-1H-imidazo[4,5-c][1,2,4]triazine (ADX10059) is a modulator of the glutamate receptor that has been studied in patients with bipolar disorder and schizophrenia. ADX10059 has been found to be safe and effective in treating both disorders. The efficacy of ADX10059 was evaluated in two clinical trials for the treatment of bipolar disorder. In the first study, ADX10059 was found to significantly reduce manic symptoms as compared to placebo. The second study showed that ADX10059 significantly reduced depressive symptoms when added to lithium or valproate therapy. A third study evaluated the effects of ADX 10059 on cognitive function in bipolar patients who were stable on lithium or valproate therapy. This study showed that ADX 10059 improves

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 509.87 g/mol
• Formule: C₂₃H₂₂ClF₆NO₃
• Degré de pureté: Min. 95%